# Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

> **NCT00455325** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 35 (actual)

## Conditions studied

- Metabolic Syndrome X
- Overweight
- Hypertension
- Dyslipidemias
- Prediabetic State

## Interventions

- **DRUG:** Placebo Comparator: First Intervention (3 weeks)
- **DRUG:** Active Comparator: Second Intervention (3 weeks)
- **DRUG:** Active Comparator: Third Intervention (3 weeks)
- **DRUG:** Active Comparator: Fourth Intervention (3 weeks)

## Key facts

- **NCT ID:** NCT00455325
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2010-06
- **Final completion:** 2012-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455325, "Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00455325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*